Advances in opioid antagonist treatment for opioid addiction.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed, 14 citations in OpenAlex.

1. Opioid use and dropout from extended-release naltrexone in a controlled trial: implications for mechanism.Addiction (Abingdon, England) · 2020
   Trial
2. Changes in fentanyl demand following naltrexone, morphine, and buprenorphine in male rats.Drug and alcohol dependence · 2020
   Article
3. Management of Opioid Addiction With Opioid Substitution Treatments: Beyond Methadone and Buprenorphine.Frontiers in psychiatry · 2018
   Review
4. Factors associated with willingness to take extended release naltrexone among injection drug users.Addiction science & clinical practice · 2015
   Article
5. Cost-Effectiveness of Injectable Extended-Release Naltrexone Compared With Methadone Maintenance and Buprenorphine Maintenance Treatment for Opioid Dependence.Substance abuse · 2015
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

3 authors at 2 institutions in 1 country.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as